Skip to content

Targeted Radiation Dose Escalation for Head and Neck Cancer with PET-CECT

Evaluating the Role of PET-CECT Based Radiation Dose Escalation in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients - A phase II, Prospective, Single Institution Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075865
Enrollment
43
Registered
2024-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00- Malignant neoplasm of lip Health Condition 2: C01- Malignant neoplasm of base of tongue Health Condition 3: C02- Malignant neoplasm of other and unspecified parts of tongue Health Condition 4: C03- Malignant neoplasm of gum Health Condition 5: C04- Malignant neoplasm of floor of mouth Health Condition 6: C05- Malignant neoplasm of palate Health Condition 7: C06- Malignant neoplasm of other and unspecified parts of mouth Health Condition 8: C07- Malignant neoplasm of paro

Interventions

Intervention1: positron emission tomography-computed tomography (PET-CECT) based radiation dose escalation in patients with head and neck cancer undergoing radical treatment: Patients will undergo PET

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1)Histologically confirmed diagnosis of HNSCC 2)Tumour sites - head and neck 3)Age - adults between 18-75 years 4)Performance status - ECOG 1-2 5)No prior head and neck radiation therapy - patients undergoing radical/ definitive RT/RT-CT 6)Patients who have understood and agreed to participate in the study by signing written informed consent including regular follow-up

Exclusion criteria

Exclusion criteria: 1)Tissue biopsy diagnosis other than HNSCC 2)Postoperative patients 3)Prior head and neck irradiation 4)Metastatic disease/ palliative status 5)Severe comorbidities 6)Pregnancy 7)Contraindications to PET-CECT 8)Patients unwilling to participate in study

Design outcomes

Primary

MeasureTime frame
Local ControlTimepoint: 3 months

Secondary

MeasureTime frame
Progression-free SurvivalTimepoint: 1 year;Overall SurvivalTimepoint: 1 year;Treatment-related toxicityTimepoint: 1 year;Quality of lifeTimepoint: 1 year

Countries

India

Contacts

Public ContactAnoushka Taneja

Kasturba Medical College, Manipal

umesh.vellu@manipal.edu8700105161

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026